Skip to Main Content
Table III.

Recognition of HSV-2 ICP0 by peptide-stimulated PBMC from HSV-2-infected, HLA-appropriate personsa

EffectorB∗4501 Target EBV-LCLNon-B∗4501 Target EBV-LCL
MockPeptideHSV-2HSV-2/anti-class IMockPeptideHSV-2
1874 PBMC 45.3 48.2 12.2 −1 
8915 PBMC 54.9 33.5 5.8 −1 
10061 PBMC 1.3 −0.6 −1.0 −1.4 0.4 0.7 0.1 
1874.1997.51 65.3 67.3 5.2 
EffectorB∗4501 Target EBV-LCLNon-B∗4501 Target EBV-LCL
MockPeptideHSV-2HSV-2/anti-class IMockPeptideHSV-2
1874 PBMC 45.3 48.2 12.2 −1 
8915 PBMC 54.9 33.5 5.8 −1 
10061 PBMC 1.3 −0.6 −1.0 −1.4 0.4 0.7 0.1 
1874.1997.51 65.3 67.3 5.2 
a

Data are percent specific release in 4-h 51Cr release assays at E:T 20:1. Each subject was HSV-2 infected and HLA B∗4501 positive. PBMC were stimulated for two cycles with peptide ICP0 92–101; see Materials and Methods. Target B∗4501-bearing (subject 1874), or non-B∗4501-bearing (subject 5085) EBV-LCL were sensitized with 1 μg/ml ICP0 92–101 for 90 min or treated with anti-class I mAb at 10 μg/ml. As a positive control, CD8 clone 1874.1997.51 was included.

Close Modal

or Create an Account

Close Modal
Close Modal